News Releases

Swedish Biomimetics 3000® Selected to Present at CleanEquity Monaco 2016

LONDON, Feb. 26, 2016 /PRNewswire/ -- Swedish Biomimetics 3000® (SB3000) will present at CleanEquity Monaco 2016 on March 3rd & 4th at the Oceanographic Museum of Monaco. 

CleanEquity Monaco 2016 (PRNewsFoto/Innovator Capital)

CleanEquity® Monaco is an annual invitation-only event hosted by Innovator Capital, the London based specialist investment bank.

SB3000 has been identified by an expert panel as one of the world's most innovative companies developing technologies for social, environmental and commercial benefit and will present to senior financial and strategic investors, policy makers, legislators, end users and media.

Other partners and sponsors include Prince Albert II of Monaco Foundation, Covington & Burling, Cranfield University, Parkview, PR Newswire, Deloitte, Gillamor Stephens, Enereau, the Monte-Carlo SBM, The Monaco Economic Board, International University of Monaco and the Oceanographic Museum of Monaco.

SB3000 has two proprietary platform technologies; the first, Micro-Lot (µLOT®), is a breakthrough technology which enables for the first time the continuous manufacture of peptides and oligonucleotides. This pharmaceutical manufacturing technology is inspired by the transcription of RNA into proteins by ribosomes and is based on an assembly line concept that enables significantly increased efficiencies in manufacturing of peptides and oligonucleotides. In addition to dramatic energy, cost and time savings, this approach simultaneously reduces any chemical and water waste from the manufacturing process.

The shift away from batch processing and towards continuous manufacturing is driven by regulatory, safety and cost pressures, but has not to date been possible for peptide manufacture given technological hurdles. Swedish Bio overcomes these hurdles and enables continuous peptide production in a therapeutic market representing $US20 billion p/a and growing.

SB3000 has recently signed an agreement with a global pharmaceutical company in relation to the µLOT® technology, providing validation of its disruptive offering to the pharmaceutical industry.

SB3000's second technology, Micro-mist (µMIST®) is a platform technology with a unique ability to spray viscous formulations without the need for harmful propellants. This has applications in consumer and potentially automotive, drug delivery and industrial applications.

Contact details for Swedish Biomimetics 3000®: Andrew J Copestake, Chief Executive Officer

Swedish Biomimetics 3000® AB,
Ingmar Bergmans Gata 2
114 34 Stockholm

About Innovator Capital

Innovator Capital is a specialist investment bank advising emerging technology companies from around the world. Established in 2003, Innovator focuses on the provision of expert strategic and capital markets advice, transaction arranging and M&A services for private and public companies.

Logo - 

SOURCE Innovator Capital